Risk Management

Giant cell arteritis

OMIC Board member Dr. Ronald W. Pelton, MD, PhD, and OMIC Patient Safety Manager Anne Menke, RN, PhD analyzed lawsuits filed by 18 patients diagnosed with giant cell arteritis (GCA) between 1993 and 2014 to determine why ophthalmologists who are familiar with GCA often fail to diagnose it.

The short window for diagnosis and treatment and the risk of severe bilateral vision loss make the high stakes of this relatively rare condition clear. Giant Cell Arteritis explores the reasons for these poor outcomes, the standard to which medical experts hold physicians who treat these patients, and the measures ophthalmologists can take to improve the likelihood of a correct and timely diagnosis.


Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Supporting your specialty.

OMIC was founded by members of the American Academy of Ophthalmology nearly a quarter century ago and is the only carrier sponsored and endorsed by AAO. OMIC is also endorsed by 54 other ophthalmic societies. The OMIC partnerships with state and subspecialty societies qualifies their members for an exclusive 10% premium credit. Contact your state society for details.